CLVS - Clovis Oncology asked by FDA to limit indication of cancer treatment Rubraca

• The FDA is asking Clovis Oncology ( NASDAQ: CLVS ) to narrow the second-line epithelial ovarian, fallopian tube, or primary peritoneal cancer indication of its treatment Rubraca (rcaparib) to tBRCA mutation patients only.
• The agency noted that if an agreement can not be reached on the matter, it would hold an advisory committee meeting.
• Clovis said it is reviewing the FDA's request.

For further details see: